Interferon beta for secondary progressive multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Recombinant interferons (IFNs) beta-1a and beta-1b are approved for Relapsing Remitting Multiple Sclerosis (RRMS).
• A key question is whether IFNs can slow or reverse the progressive phase of MS.
• This review focuses on the efficacy of IFNs in Secondary Progressive Multiple Sclerosis (SPMS).

Purpose of the Study:

• To determine if interferon (IFN) beta treatment is more effective than placebo in reducing disability progression in SPMS patients.
• To analyze the impact of IFNs on relapse rates and MRI-defined disease activity in SPMS.

Main Methods:

• Systematic review of randomized, placebo-controlled trials (RCTs) of IFNs versus placebo in SPMS.
• Searches included Cochrane MS Trials Register, reference lists, and regulatory agencies.
• Data extraction and risk of bias assessment were performed independently by two reviewers.

Main Results:

• Five RCTs involving 3122 patients (1829 IFN, 1293 placebo) were analyzed.
• IFN beta did not reduce the risk of sustained disability progression at 6 months over three years.
• A significant reduction in 3-month sustained progression and new relapses at three years was observed.
• MRI data suggested a decrease in active brain lesions, despite no effect on clinical progression.
• The safety profile of IFNs was consistent with known side effects in MS patients.

Conclusions:

• Recombinant IFN beta does not prevent the development of permanent physical disability in SPMS.
• IFN treatment significantly reduces the risk of relapses and short-term disability.
• The anti-inflammatory effects of IFNs do not halt established disease progression in SPMS.